Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

Published:2008-11-27 Issue:3 Volume:23 Page:477-485
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Remsing Rix L L,Rix U,Colinge J,Hantschel O,Bennett K L,Stranzl T,Müller A,Baumgartner C,Valent P,Augustin M,Till J H,Superti-Furga G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2008334.pdf

Reference35 articles.

1. Jabbour E, Cortes JE, Giles FJ, O’Brien S, Kantarjian HM . Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109: 2171–2181.

2. Druker BJ . Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1–30.

3. Druker BJ . Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354: 2594–2596.

4. Shah NP, Sawyers CL . Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389–7395.

5. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.

Cited by 241 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia;Annals of Hematology;2024-07-18

2. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain;Blood;2024-05-23

3. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors;European Journal of Pharmacology;2024-05

4. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05

5. Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase;ACS Chemical Biology;2024-03-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3